Delving into the Latest Updates on Fozivudine tidoxil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Fozivudine, FZT, BM 21.1290

+ [8]

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Heidelberg Pharma AG

Active Organization-

Inactive Organization

Ludwig-Maximilians-Universität München

Heidelberg Pharma AG

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC35H64N5O8PS

InChIKeyIBHARWXWOCPXCR-WELGVCPWSA-N

CAS Registry141790-23-0

A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naïve, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast

A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based antiretroviral therapy regimen after 24 weeks of treatment in ART naïve, non subtype B HIV-1 infected individuals from Tanzania and Ivory Coast.

Start Date01 Dec 2012

Sponsor / Collaborator

Ludwig-Maximilians-Universität München

[+5]

PACTR201205000384379

/ CompletedPhase 2IIT

A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naïve, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast

Start Date01 Aug 2012

Sponsor / Collaborator-

NCT00002385

/ CompletedNot Applicable

Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).

To identify doses of fozivudine tidoxil that are well tolerated and produce measurable antiviral activity.
To identify the adverse event profile that defines the maximum tolerated dose. To characterize the single- and multiple-dose pharmacokinetics of fozivudine and its metabolites.
To correlate the adverse event profile and antiviral activity of fozivudine with pharmacokinetic parameters.

Start Date-

Sponsor / Collaborator

Anderson Clinical Research

[+1]

100 Clinical Results associated with Fozivudine tidoxil

Login to view more data

100 Translational Medicine associated with Fozivudine tidoxil

Login to view more data

100 Patents (Medical) associated with Fozivudine tidoxil

Login to view more data

57

Literatures (Medical) associated with Fozivudine tidoxil

01 Dec 2025·FOOD CHEMISTRY

Tracing antibiotics in food through dual-mode ratiometric luminescence core-shell nanoparticles

Article

Author: Gadiyaram, Srushti ; Aleem, Abdur Raheem ; Wu, Hanxiang ; Hakeem, Deshmukh Abdul ; Song, Wei ; Yu, Lin ; Li, Qi ; Wen, Hongli ; Gao, Xin

Tracing antibiotics from food is crucial and challenging due to the widespread global implementation of antibiotics for animal disease prevention and controls, which could potentially cause serious health risks in humans. Herein, rare earth doped nanoparticles (RENPs) with amino-SiO₂ modification were designed for dual-mode luminescence sensing of furazolidone (FZD) antibiotic. FZD extensively suppressed the UV upconversion luminescence (UCL), keeping the green UCL unchanged as the internal reference; the downconversion luminescence (DCL) was significantly quenched by FZD. The RENPs@SiO₂-NH₂ nanoprobe exhibited UCL ratiometric and DCL sensing with high sensitivity and specific recognition towards FZD in linear ranges of 0.05-300 and 1-300 μmol·L^-1, with 0.033 and 0.064 μmol·L^-1 LOD, respectively. The RENPs@SiO₂-NH₂ nanoprobe was validated using FZD reference material with recoveries in range of 96-114 %, and successfully detecting FZD from milk and chicken meat samples. The proposed dual mode luminescence nanoprobe is promising for precise and specific FZD determination in food samples.

20 Nov 2025·JOURNAL OF INFECTIOUS DISEASES

Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients

Article

Author: Song, Xiaona ; Li, Hong ; Zhang, Yupei ; Marshall, Barry J ; Liu, Kai ; Tang, Hong ; Shen, Yalin ; Tay, Alfred

Abstract:

Background:

The increasing antibiotic resistance of Helicobacter pylori poses challenges in selecting effective eradication therapies for patients with gastric cancer. This study aimed to assess the antibiotic resistance patterns of clinical H. pylori strains isolated from gastric cancer patients, to guide H. pylori eradication strategies for those with residual gastric mucosa after gastrectomy.

Methods:

This study enrolled 115 consecutive patients with gastric cancer who had a positive 13C urea breath test, all of whom were scheduled for gastric resection at West China Hospital of Sichuan University. Gastric mucosa samples were collected for pathological examination, H. pylori culture, and susceptibility testing using E-test and disk diffusion methods.

Results:

From 115 specimens, 86 H. pylori strains were cultured (74.8% culture rate). Of the 86 patients (59 males, 27 females; median age 59, range 34–79) with successful H. pylori isolation, histopathology revealed 37 intestinal-type, 27 diffuse-type, 9 mixed-type, and 13 unclassified gastric cancers. Sixty-one patients underwent distal gastrectomy, and 25 had radical total gastrectomy. Notably, 12 patients were diagnosed at ≤45 years, including 9 females, all with signet ring cell carcinoma. Antibiotic resistance rates were rifampicin (RIF) (69.8%), metronidazole (MTZ) (75.6%), clarithromycin (CLR) (41.9%), levofloxacin (LEV) (32.6%), amoxicillin (AML) (2.3%), tetracycline (TET) (1.2%), and furazolidone (FZD) (0%).

Conclusions:

H. pylori isolates from gastric cancer patients exhibited high resistance to RIF, MTZ, CLR, and LEV, but negligible resistance to AML, FZD, and TET. Given the compromised health status and need for concurrent therapies in these patients, AML- and/or minocycline-based regimens may represent a practical and effective treatment option for H. pylori eradication in gastric cancer patients with residual gastric mucosa after distal gastrectomy, to reduce the risk of metachronous gastric cancer.

20 Nov 2025·JOURNAL OF INFECTIOUS DISEASES

Follow-up and Analysis of Helicobacter pylori Antibioic Resistance in the South Area of Sichuan Province

Article

Author: Li, Changping ; Li, Ying ; Xu, Mei ; Liang, Chunhong ; Zhou, Yuyang

Abstract:

Background:

The antibiotic resistance rate of Helicobacter pylori (H. pylori) has increased year by year with the widespread use of antibiotics, resulting in reduced efficacy of eradication therapy and increased recurrence rate. We conducted a survey on H. pylori resistance in the South area of Sichuan province to provide guidance for front-line treatments of H. pylori in this area.

Methods:

Helicobacter pylori strains were isolated from gastric mucosa specimens obtained from patients with suspected H. pylori infection from the South area of Sichuan province. Antibiotic susceptibility of the strains was determined by disk diffusion method.

Results:

Among 373 patients, 323 were from southern Sichuan. H. pylori strains were isolated and cultured from gastric mucosa samples of 304 patients, resulting in an isolation and culture success rate of 81.50%. Metronidazole (MNZ) is the antibiotic with the highest drug resistance rate in the South area of Sichuan province, with a drug resistance rate as high as 98.68%. The resistance rates of amoxicillin and furazolidone were very low, accounting for 0.29% and 0.99%, respectively. However, tetracycline showed no resistance. Single antibiotic resistance accounted for 35.67%, while the resistance to 2 antibiotics was dual resistance, accounting for 34.67%. Dual drug resistance was mainly MNZ and levofloxacin, followed by MNZ and clarithromycin (CLA).

Conclusions:

MNZ, levofloxacin, and CLA should be used cautiously in H. pylori eradication therapy in the South area of Sichuan province. If the cultivation results and drug sensitivity test results of the H. pylori strain cannot be obtained, it is recommended to adopt an empirical treatment plan, using the pairwise combinations of amoxicillin, tetracycline, and FZD, especially the combination of amoxicillin and tetracycline.

100 Deals associated with Fozivudine tidoxil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12423

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	Côte d'Ivoire	Ludwig-Maximilians-Universität München	01 Dec 2012
HIV Infections	Phase 2	Tanzania	Ludwig-Maximilians-Universität München	01 Dec 2012